Chronic obstructive pulmonary disease, unspecified. Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Intervention 1: Group A(Placebo): Patients receives standard treatment for COPD as recommended by the GOLD guidelines plus placebo capsule (sesame oil), similar in appearance to active drug in group
Placebo
Treatment - Drugs
Group A(Placebo): Patients receives standard treatment for COPD as recommended by the GOLD guidelines plus placebo capsule (sesame oil), similar in appearance to active drug in group B and C, one ca
Group B: Patients receives standard treatment for COPD as recommended by the GOLD guidelines plus vitamin D ,25 (OH)-D3 (Pourateb, Iran) 50000 IU, one capsule daily for a week.
Group C: Patients receives standard treatment for COPD as recommended by the GOLD guidelines plus Calcitriol, 1, 25 (OH)2-D3 (Pourateb, Iran) 0.25 µg, one capsule daily for a week.
Sponsors
Vice chancellor for research, Kerman University of Medical Sciences PhYsiology resaerch center of
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Including criteria: 1.Having COPD exacerbation 2.Age between 40 and 60 years 3.Moderate to severe disease. Exclusion criteria 1.Unwillingness to participate in the study, 2.Unable to perform spirometry, 3.History of any other respiratory disorder including asthma , bronchial carcinoma,lower respiratory tract infection 4. Recent (within 4 wk) hospitalization for COPD, 6.Any medical condition which needed more invasive respiratory support,6.Evidence of hypercalcemia, renal failure, hyperparathyroidism, malignancy, history of renal stone, cardiac arrhythmia, or patients who were using lithium.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 25(OH)2vit D3. Timepoint: first and 8th day. Method of measurement: Enzyme assay.;1,25(oh)2vitD3. Timepoint: first and 8th day. Method of measurement: Enzyme assay.;FEV1 and FVC. Timepoint: 8th day. Method of measurement: spirometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| C Reactive Protein,CRP. Timepoint: first and 8th day. Method of measurement: latex-enhanced immunoturbidimetric assay.;Serum Total Antioxidant. Timepoint: first and 8th day. Method of measurement: Calorimetry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Dr. Mojgan Sanjari
Kerman university of Medical sciences
Outcome results
None listed